|
|
dmLT (double mutant of heat-labile E.coli) |
|
Vaxjo ID |
129 |
|
Vaccine Adjuvant Name |
dmLT (double mutant of heat-labile E.coli) |
|
Adjuvant VO ID |
VO_0005329
|
|
Description |
A vaccine adjuvant that includes double mutant of heat-labile E. coli toxin (LT) at R192G/L211A or LT(R192G/L211A) |
|
Stage of Development |
Clinical Trial |
|
Location Licensed |
US (Tulane University) |
|
Host Species for Testing |
Human |
|
Second Host Species for Testing |
Mouse |
|
Components |
dmLT and LTA1 --> have an enzymatic A-subunit = ADP-ribosylates Gsα |
|
Storage |
Store lyophilized at 4C, upon resuspension store short-term at 4C or long-term frozen. Storage in glass vials at highly diluted concentrations without antigen not recommended |
|
Preparation |
derived from the heat-labile toxin of E. coli including dmLT and LTA1 |
|
Function |
Type: microbial derivative vaccine adjuvant. Induces Th1/Th17 mixed immune profile. cAMP, activates NLRP3 inflammasome, GM1-binding; Induces mucosal immunity, Induces epitope spreading, forms a depot for antigen release, Promotes antibody affinity maturation, Effective in newborns, Promotes antibody epitope spreading |
| References |
(Norton, 2021): Vaccine Adjuvant Compendium (VAC) [https://vac.niaid.nih.gov/view?id=13]
Clements and Norton, 2018: Clements JD, Norton EB. The Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLT. mSphere. 2018; 3(4); . [PubMed: 30045966].
Norton et al., 2011: Norton EB, Lawson LB, Freytag LC, Clements JD. Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant. Clinical and vaccine immunology : CVI. 2011; 18(4); 546-551. [PubMed: 21288994].
|
|
